Industrial - Machinery
Compare Stocks
5 / 10Stock Comparison
OTIS vs CARR vs TT vs JCI vs EMR
Revenue, margins, valuation, and 5-year total return — side by side.
Construction
Construction
Construction
Industrial - Machinery
OTIS vs CARR vs TT vs JCI vs EMR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Industrial - Machinery | Construction | Construction | Construction | Industrial - Machinery |
| Market Cap | $30.11B | $56.07B | $103.99B | $85.23B | $79.02B |
| Revenue (TTM) | $14.65B | $21.87B | $21.60B | $24.43B | $18.32B |
| Net Income (TTM) | $1.48B | $1.32B | $2.90B | $3.53B | $2.44B |
| Gross Margin | 30.4% | 24.8% | 35.9% | 36.6% | 52.7% |
| Operating Margin | 15.4% | 8.1% | 18.2% | 13.6% | 19.8% |
| Forward P/E | 18.4x | 24.2x | 31.7x | 29.4x | 21.7x |
| Total Debt | $8.75B | $12.67B | $4.62B | $11.19B | $13.76B |
| Cash & Equiv. | $1.10B | $1.55B | $1.76B | $379M | $1.54B |
OTIS vs CARR vs TT vs JCI vs EMR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Otis Worldwide Corp… (OTIS) | 100 | 147.1 | +47.1% |
| Carrier Global Corp… (CARR) | 100 | 327.8 | +227.8% |
| Trane Technologies … (TT) | 100 | 520.8 | +420.8% |
| Johnson Controls In… (JCI) | 100 | 443.3 | +343.3% |
| Emerson Electric Co. (EMR) | 100 | 231.2 | +131.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OTIS vs CARR vs TT vs JCI vs EMR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
OTIS carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 6 yrs, beta 0.39, yield 2.1%
- Beta 0.39, yield 2.1%, current ratio 0.85x
- Lower P/E (18.4x vs 21.7x), PEG 1.67 vs 4.81
- Beta 0.39 vs EMR's 1.52
CARR lags the leaders in this set but could rank higher in a more targeted comparison.
TT ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 7.5%, EPS growth 15.5%, 3Y rev CAGR 10.1%
- 8.7% 10Y total return vs JCI's 343.3%
- Lower volatility, beta 0.97, Low D/E 53.7%, current ratio 1.25x
- PEG 1.06 vs EMR's 4.81
JCI is the #2 pick in this set and the best alternative if quality and momentum is your priority.
- 14.5% margin vs CARR's 6.0%
- +56.9% vs OTIS's -18.7%
Among these 5 stocks, EMR doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.5% revenue growth vs CARR's -3.3% | |
| Value | Lower P/E (18.4x vs 21.7x), PEG 1.67 vs 4.81 | |
| Quality / Margins | 14.5% margin vs CARR's 6.0% | |
| Stability / Safety | Beta 0.39 vs EMR's 1.52 | |
| Dividends | 2.1% yield, 6-year raise streak, vs EMR's 1.5% | |
| Momentum (1Y) | +56.9% vs OTIS's -18.7% | |
| Efficiency (ROA) | 14.0% ROA vs CARR's 3.5%, ROIC 78.1% vs 6.7% |
OTIS vs CARR vs TT vs JCI vs EMR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
OTIS vs CARR vs TT vs JCI vs EMR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
TT leads in 2 of 6 categories
EMR leads 1 • OTIS leads 1 • CARR leads 0 • JCI leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
EMR leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JCI is the larger business by revenue, generating $24.4B annually — 1.7x OTIS's $14.6B. JCI is the more profitable business, keeping 14.5% of every revenue dollar as net income compared to CARR's 6.0%. On growth, JCI holds the edge at +8.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $14.6B | $21.9B | $21.6B | $24.4B | $18.3B |
| EBITDAEarnings before interest/tax | $2.4B | $3.1B | $4.3B | $3.9B | $4.7B |
| Net IncomeAfter-tax profit | $1.5B | $1.3B | $2.9B | $3.5B | $2.4B |
| Free Cash FlowCash after capex | $1.7B | $1.7B | $3.2B | $1.4B | $3.1B |
| Gross MarginGross profit ÷ Revenue | +30.4% | +24.8% | +35.9% | +36.6% | +52.7% |
| Operating MarginEBIT ÷ Revenue | +15.4% | +8.1% | +18.2% | +13.6% | +19.8% |
| Net MarginNet income ÷ Revenue | +10.1% | +6.0% | +13.4% | +14.5% | +13.3% |
| FCF MarginFCF ÷ Revenue | +11.4% | +7.6% | +14.6% | +5.7% | +17.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.4% | +2.4% | +6.0% | +8.2% | +2.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +42.6% | -40.4% | -1.9% | +38.9% | +28.2% |
Valuation Metrics
OTIS leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 22.1x trailing earnings, OTIS trades at a 58% valuation discount to JCI's 52.9x P/E. Adjusting for growth (PEG ratio), TT offers better value at 1.21x vs EMR's 7.73x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $30.1B | $56.1B | $104.0B | $85.2B | $79.0B |
| Enterprise ValueMkt cap + debt − cash | $37.8B | $67.2B | $106.8B | $96.0B | $91.2B |
| Trailing P/EPrice ÷ TTM EPS | 22.13x | 39.48x | 36.20x | 52.95x | 34.92x |
| Forward P/EPrice ÷ next-FY EPS est. | 18.36x | 24.18x | 31.69x | 29.38x | 21.71x |
| PEG RatioP/E ÷ EPS growth rate | 2.02x | — | 1.21x | 2.06x | 7.73x |
| EV / EBITDAEnterprise value multiple | 16.36x | 21.71x | 25.25x | 26.01x | 18.07x |
| Price / SalesMarket cap ÷ Revenue | 2.09x | 2.58x | 4.88x | 3.61x | 4.39x |
| Price / BookPrice ÷ Book value/share | — | 4.02x | 12.21x | 7.03x | 3.94x |
| Price / FCFMarket cap ÷ FCF | 20.85x | 33.04x | 36.99x | 88.32x | 29.63x |
Profitability & Efficiency
TT leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
TT delivers a 34.7% return on equity — every $100 of shareholder capital generates $35 in annual profit, vs $9 for CARR. TT carries lower financial leverage with a 0.54x debt-to-equity ratio, signaling a more conservative balance sheet compared to CARR's 0.90x. On the Piotroski fundamental quality scale (0–9), TT scores 9/9 vs CARR's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +9.1% | +34.7% | +24.9% | +12.1% |
| ROA (TTM)Return on assets | +14.0% | +3.5% | +13.4% | +9.0% | +5.8% |
| ROICReturn on invested capital | +78.1% | +6.7% | +26.2% | +8.5% | +8.2% |
| ROCEReturn on capital employed | +65.0% | +7.2% | +27.2% | +9.8% | +10.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 9 | 6 | 7 |
| Debt / EquityFinancial leverage | — | 0.90x | 0.54x | 0.86x | 0.68x |
| Net DebtTotal debt minus cash | $7.7B | $11.1B | $2.9B | $10.8B | $12.2B |
| Cash & Equiv.Liquid assets | $1.1B | $1.6B | $1.8B | $379M | $1.5B |
| Total DebtShort + long-term debt | $8.8B | $12.7B | $4.6B | $11.2B | $13.8B |
| Interest CoverageEBIT ÷ Interest expense | 10.77x | 5.76x | 17.21x | 18.41x | 6.46x |
Total Returns (Dividends Reinvested)
TT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TT five years ago would be worth $26,428 today (with dividends reinvested), compared to $10,767 for OTIS. Over the past 12 months, JCI leads with a +56.9% total return vs OTIS's -18.7%. The 3-year compound annual growth rate (CAGR) favors TT at 39.5% vs OTIS's -1.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -11.8% | +26.3% | +18.3% | +14.2% | +4.3% |
| 1-Year ReturnPast 12 months | -18.7% | -2.8% | +16.3% | +56.9% | +30.4% |
| 3-Year ReturnCumulative with dividends | -4.3% | +63.4% | +171.7% | +127.9% | +75.9% |
| 5-Year ReturnCumulative with dividends | +7.7% | +58.0% | +164.3% | +122.9% | +59.5% |
| 10-Year ReturnCumulative with dividends | +87.8% | +493.6% | +874.8% | +343.3% | +206.6% |
| CAGR (3Y)Annualised 3-year return | -1.5% | +17.8% | +39.5% | +31.6% | +20.7% |
Risk & Volatility
Evenly matched — OTIS and JCI each lead in 1 of 2 comparable metrics.
Risk & Volatility
OTIS is the less volatile stock with a 0.39 beta — it tends to amplify market swings less than EMR's 1.52 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JCI currently trades 94.5% from its 52-week high vs OTIS's 76.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.39x | 1.19x | 0.97x | 0.97x | 1.52x |
| 52-Week HighHighest price in past year | $101.42 | $81.09 | $503.47 | $147.32 | $165.15 |
| 52-Week LowLowest price in past year | $75.27 | $50.24 | $348.06 | $87.77 | $108.37 |
| % of 52W HighCurrent price vs 52-week peak | +76.4% | +82.8% | +93.3% | +94.5% | +85.4% |
| RSI (14)Momentum oscillator 0–100 | 41.4 | 64.2 | 62.2 | 56.2 | 61.3 |
| Avg Volume (50D)Average daily shares traded | 3.5M | 6.6M | 1.2M | 3.3M | 2.8M |
Analyst Outlook
Evenly matched — OTIS and EMR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: OTIS as "Hold", CARR as "Buy", TT as "Hold", JCI as "Buy", EMR as "Buy". Consensus price targets imply 18.8% upside for OTIS (target: $92) vs -0.9% for JCI (target: $138). For income investors, OTIS offers the higher dividend yield at 2.12% vs TT's 0.80%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $92.00 | $67.50 | $518.50 | $138.00 | $161.92 |
| # AnalystsCovering analysts | 13 | 26 | 25 | 45 | 41 |
| Dividend YieldAnnual dividend ÷ price | +2.1% | +1.4% | +0.8% | +1.1% | +1.5% |
| Dividend StreakConsecutive years of raises | 6 | 6 | 5 | 5 | 37 |
| Dividend / ShareAnnual DPS | $1.64 | $0.91 | $3.74 | $1.49 | $2.10 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.7% | +5.2% | +1.4% | +7.0% | +1.6% |
TT leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). EMR leads in 1 (Income & Cash Flow). 2 tied.
OTIS vs CARR vs TT vs JCI vs EMR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is OTIS or CARR or TT or JCI or EMR a better buy right now?
For growth investors, Trane Technologies plc (TT) is the stronger pick with 7.
5% revenue growth year-over-year, versus -3. 3% for Carrier Global Corporation (CARR). Otis Worldwide Corporation (OTIS) offers the better valuation at 22. 1x trailing P/E (18. 4x forward), making it the more compelling value choice. Analysts rate Carrier Global Corporation (CARR) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — OTIS or CARR or TT or JCI or EMR?
On trailing P/E, Otis Worldwide Corporation (OTIS) is the cheapest at 22.
1x versus Johnson Controls International plc at 52. 9x. On forward P/E, Otis Worldwide Corporation is actually cheaper at 18. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Trane Technologies plc wins at 1. 06x versus Emerson Electric Co. 's 4. 81x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — OTIS or CARR or TT or JCI or EMR?
Over the past 5 years, Trane Technologies plc (TT) delivered a total return of +164.
3%, compared to +7. 7% for Otis Worldwide Corporation (OTIS). Over 10 years, the gap is even starker: TT returned +874. 8% versus OTIS's +87. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — OTIS or CARR or TT or JCI or EMR?
By beta (market sensitivity over 5 years), Otis Worldwide Corporation (OTIS) is the lower-risk stock at 0.
39β versus Emerson Electric Co. 's 1. 52β — meaning EMR is approximately 288% more volatile than OTIS relative to the S&P 500. On balance sheet safety, Trane Technologies plc (TT) carries a lower debt/equity ratio of 54% versus 90% for Carrier Global Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — OTIS or CARR or TT or JCI or EMR?
By revenue growth (latest reported year), Trane Technologies plc (TT) is pulling ahead at 7.
5% versus -3. 3% for Carrier Global Corporation (CARR). On earnings-per-share growth, the picture is similar: Emerson Electric Co. grew EPS 17. 8% year-over-year, compared to -72. 4% for Carrier Global Corporation. Over a 3-year CAGR, TT leads at 10. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — OTIS or CARR or TT or JCI or EMR?
Johnson Controls International plc (JCI) is the more profitable company, earning 13.
9% net margin versus 6. 9% for Carrier Global Corporation — meaning it keeps 13. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EMR leads at 19. 6% versus 9. 9% for CARR. At the gross margin level — before operating expenses — EMR leads at 52. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is OTIS or CARR or TT or JCI or EMR more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Trane Technologies plc (TT) is the more undervalued stock at a PEG of 1. 06x versus Emerson Electric Co. 's 4. 81x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Otis Worldwide Corporation (OTIS) trades at 18. 4x forward P/E versus 31. 7x for Trane Technologies plc — 13. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OTIS: 18. 8% to $92. 00.
08Which pays a better dividend — OTIS or CARR or TT or JCI or EMR?
All stocks in this comparison pay dividends.
Otis Worldwide Corporation (OTIS) offers the highest yield at 2. 1%, versus 0. 8% for Trane Technologies plc (TT).
09Is OTIS or CARR or TT or JCI or EMR better for a retirement portfolio?
For long-horizon retirement investors, Trane Technologies plc (TT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
97), 0. 8% yield, +874. 8% 10Y return). Emerson Electric Co. (EMR) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TT: +874. 8%, EMR: +206. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between OTIS and CARR and TT and JCI and EMR?
Both stocks operate in the Industrials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.